title: Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with (131)I: comparison of the efficacy of pantoprazole, metoclopramide, and ondansetron - a randomized clinical trial.
abstract: OBJECTIVE
  To compare safety and efficacy of pantoprazol , metoclopramide, ondansetron, as compared to placebo, in controlling gastrointestinal (GI) complaints of thyroid cancer patients treated with I-131these patients.
  
  
  METHODS
  Four-armed, parallel group, single blind, randomized controlled clinical trial, setting: A university hospital, registration: database for clinical trials IRCT2013061713705N1.
  
  
  METHODS
  85 patients with differentiated thyroid cancer who received 131I.
  
  
  METHODS
  Postradioiodine nausea and vomiting within three days of therapy (primary endpoint); occurrence of adverse reaction.
  
  
  RESULTS
  The patients' characteristics were similar within the study groups. Among the study variables, age, sex, administered dosage, history of previous GI complaints, and history of hyperemesis gravidarum in female patients were not statistically different among the groups (p > 0.05). The results revealed that only ondansetron shows a therapeutic benefit over the placebo in controlling nausea (p < 0.05); however, it does not prevent vomiting (p > 0.05). The other two drugs, pantoprazole and metoclopramide, did not control nausea (p > 0.05) or vomiting (p > 0.05).
  
  
  CONCLUSIONS
  This study may demonstrate that the therapeutic dose of ondansetron could be an effective prophylactic agent in controlling GI complaints in differential thyroid carcinoma (DTC) patients following RAI therapy; however, these preliminary findings should be validated in larger studies.
authors: M
authors: M
authors: Mirzababaee
authors: B
authors: B
authors: Shafiei
authors: S
authors: S
authors: Seifollahi
authors: M
authors: M
authors: Motazdian
authors: L
authors: L
authors: Fatholahi
authors: S
authors: S
authors: Delavari
authors: R
authors: R
authors: Naghshine
authors: N
authors: N
authors: Baharfar
authors: F
authors: F
authors: Tabeie
authors: H
authors: H
authors: Javadi
authors: Majid Assadi, MD, The Persian Gulf Nuclear Medicine Research Center, University of Medical Sciences, Bushehr 3631, Iran, Tel. +98/771/258 01 69, Fax +98/771/254 18 28.
authors: M
authors: M
authors: Assadi
authors: I N
authors: IN
authors: Asli
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000932:Antiemetics / Q000627:therapeutic use; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use*; D008875:Middle Aged; D017294:Ondansetron / Q000627:therapeutic use*; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000150:complications / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000932:Antiemetics; D007457:Iodine Radioisotopes; D054328:Proton Pump Inhibitors; D019275:Radiopharmaceuticals; D017294:Ondansetron; D000077402:Pantoprazole; D008787:Metoclopramide
keywords: Differentiated thyroid cancer; gastrointestinal complaint; metoclopramide; ondansetron; pantoprazole